United States Health

Creative Medical Technology Holdings (NASDAQ:CELZ) reported that 28 of 30 patients, or 93%, met study-defined response criteria in its Ultrasome knee osteoarthritis pilot.

Rapport Therapeutics (NASDAQ:RAPP) reported that its Phase 2 trial of RAP-219 in adults with acute bipolar mania met both primary and secondary endpoints.

Alvotech (NASDAQ:ALVO) received FDA approval for a manufacturing process that more than doubles SIMLANDI drug substance output per batch at its Iceland facility.

Anteris Technologies Global (NASDAQ:AVR) received full German regulatory clearance to recruit patients for its global PARADIGM trial evaluating the DurAVR heart valve.

Oracle (NYSE:ORCL) announced a non-binding collaboration with AstraZeneca (NASDAQ:AZN) to explore artificial intelligence and real-world data applications in clinical research.

Oculis (NASDAQ:OCS) will present new Phase 2 ACUITY biomarker analyses of its investigational Privosegtor treatment on October 22, 2026, in Toronto.

Kenvue (NYSE:KVUE) lost its bid to reconsider a federal appeals ruling reviving approximately 500 lawsuits alleging prenatal Tylenol exposure caused autism or ADHD.

United Therapeutics (NASDAQ:UTHR) received FDA clearance to proceed with a Phase 2 trial of treprostinil SMI for pulmonary hypertension associated with COPD.

Cullinan Therapeutics (NASDAQ:CGEM) and Taiho Oncology reported a 30.2% intracranial response rate for zipalertinib in 43 evaluable lung cancer patients with brain metastases.

Summit Therapeutics (NASDAQ:SMMT) announced the opening of a Phase 2 kidney cancer trial evaluating ivonescimab-based treatments in approximately 100 patients across two countries.

Veradermics (NYSE:MANE) reported positive Phase 3 results for VDPHL01, with both dosing regimens significantly increasing hair counts versus placebo after six months.

Cosmos Health (NASDAQ:COSM) forecasts approximately $15 million in fourth-quarter 2026 U.S. direct-to-consumer revenue, with projected gross profit of $10.5 million.

The forecast represents a 70% gross margin for its U.S. online business, compared with roughly 8% company-wide GAAP gross margin in Q2.